Relevant bibliographies by topics / Anti-cancer

Academic literature on the topic 'Anti-cancer'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti-cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anti-cancer"

1

Tyagi, Nidhi, Ganesh N. Sharma, Birendra Shrivastava, Prasoon Saxena, and Nitin Kumar. "Medicinal plants: used in Anti-cancer treatment." International Journal of Research and Development in Pharmacy & Life Sciences 6, no. 5 (August 2017): 2732–39. http://dx.doi.org/10.21276/ijrdpl.2278-0238.2017.6(5).2732-2739.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dr Anand Kumar, Dr Anand Kumar, and *. Dr RuchikaKhanna * Dr RuchikaKhanna. "Glutathione A Super Anti-Oxidant in Preventing Oral Cancer." International Journal of Scientific Research 3, no. 5 (June 1, 2012): 423–24. http://dx.doi.org/10.15373/22778179/may2014/133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hoefnagel, Cornelis A. "Anti-cancer radiopharmaceuticals." Anti-Cancer Drugs 2, no. 2 (April 1991): 107–32. http://dx.doi.org/10.1097/00001813-199104000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

D, Devananda. "Annona Muricata (Linn.) Acetogenins as Potent Anti-Breast Cancer Agents." International Journal of Pharmacognosy & Chinese Medicine 4, no. 2 (2020): 1–8. http://dx.doi.org/10.23880/ipcm-16000202.

Full text
Abstract:
Breast cancer is the most common type of cancer in women, globally. In India, it has been ranked number one with regard to cancer incidence in both men and women. Phytotherapy has been extensively considered against cancer, and Annona muricata is one such plant species that has gained scientific interest for decades. The acetogenins, a class of phytocompounds exclusively to the Annonaceae family of plant kingdom, are known contributors towards this biomedical significance of the A. muricata. In this review, we have identified those A. muricata acetogenins that exhibit anti-breast cancer activity.
APA, Harvard, Vancouver, ISO, and other styles
5

Gupta, Tarun, Virendra Kumar Vishwakarma, and Manoj Kumar Maurya Khushdil Khan. "Anti-cancer Activity of Vitamin-C Against Leukemia: A Review." International Journal of Trend in Scientific Research and Development Volume-2, Issue-4 (June 30, 2018): 1264–72. http://dx.doi.org/10.31142/ijtsrd14250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Moku, Gopikrishna, Suresh Kumar Gulla, Narendra Varma Nimmu, Sara Khalid, and Arabinda Chaudhuri. "Delivering anti-cancer drugs with endosomal pH-sensitive anti-cancer liposomes." Biomaterials Science 4, no. 4 (2016): 627–38. http://dx.doi.org/10.1039/c5bm00479a.

Full text
Abstract:
Numerous prior studies have been reported on the use of pH-sensitive drug carriers such as micelles, liposomes, peptides, polymers, nanoparticles,etc. that are sensitive to the acidic (pH = ∼6.5) microenvironments of tumor tissues.
APA, Harvard, Vancouver, ISO, and other styles
7

Tahara, Makoto. "Anti-cancer drugs for thyroid cancer." Annals of Oncology 28 (October 2017): ix63. http://dx.doi.org/10.1093/annonc/mdx612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

D, Dinesh M., Neethu George, and Abdul Bari K. K. Hima K. U. S. Meenatchisundaram. "In vitro anti-cancer activity of Piper betel leaf extract on HA -29 and its anti-oxidant activity." International Journal of Trend in Scientific Research and Development Volume-2, Issue-4 (June 30, 2018): 289–92. http://dx.doi.org/10.31142/ijtsrd12926.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

H Tan, Peng, Mingrui Xie, and Eleftherios Sfakianakis. "Complex interaction of adipokines in breast cancer and anti-tumour immunity; a new paradigm for cancer treatment." Cancer Research and Cellular Therapeutics 5, no. 2 (June 9, 2021): 01–16. http://dx.doi.org/10.31579/2640-1053/077.

Full text
Abstract:
Obesity and its related complications have been the pressing disease pandemic affecting the developed world. It is well-established that the direct consequence of obesity in the cardiovascular system resulting in many diseases. However, its implications in carcinogenesis, cancer treatment and one’s anti-tumour immunity are gradually unfolding. To understand how fat cells can affect these, one needs to explore how the fat cell affects epithelial and immune cells. To this end, we explore the way how the adipocytes, via its production of adipokines, influence these cells, resulting in early epithelial cell transformation into cancer cells and influencing anti-tumour immunity once the cancer is established. In order to simplify our discussion, we focus this review on breast cancer. We propose that to have an effective therapy for cancer treatment, we need to intervene at the adipokine interaction with epithelial cells, cancer cells, and immune cells. In this review we also decipher the potential therapeutic targets in controlling carcinogenesis and disease progression.
APA, Harvard, Vancouver, ISO, and other styles
10

Galaup, A., C. Magnon, P. Opolon, M. Pérricaudet, and F. Griscelli. "Anti-angiogenèse et cancer." Journal des Maladies Vasculaires 29 (March 2004): 13–14. http://dx.doi.org/10.1016/s0398-0499(04)96803-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anti-cancer"

1

Wheate, Nial Joseph Chemistry Australian Defence Force Academy UNSW. "Platinum anti-cancer complexes." Awarded by:University of New South Wales - Australian Defence Force Academy. School of Chemistry, 2001. http://handle.unsw.edu.au/1959.4/38704.

Full text
Abstract:
[Formulae and special characters can only be approximated here. Please see the pdf version of the Abstract for an accurate reproduction.] Several inert platinum complexes were synthesised: [(en)Pt([special character]-dpzm)2Pt(en)]4+, [{Pt(dien)}2[special character]-dpzm]4+, [{Pt(dien)}2[special character]-H2N-(CH2)6-NH2]4+, cis-[(NH3)2Pt([special character]--dpzm)2Pt(NH3)2]4+, trans-[Pt(NH3)2([special character]-dpzm)2]2+. Three active complexes, all with chloro ligands, were also synthesised: trans-[{Pt(NH3)Cl2}2[special character]-dpzm)], trans-[{Pt(NH3)2Cl}2[special character]-dpzm]2+ (di-Pt) and trans-[trans-{Pt(NH3)2Cl}2{trans-[Pt(NH3)2([special character]-dpzm)2]}]4+ (tri-Pt). 1H NMR established that multi-nuclear platinum complexes will preferentially associate in the DNA minor groove with a preference for A/T sequences, and with a binding constant [special character]-105 M-1, regardless of the charge, linking ligand, length or shape. Using [(en)Pt([special character]-dpzm)2Pt(en)]4+ and the oligonucleotide d(GC)5 it was determined that the metal complex binds G/C rich sequences also in the minor groove, but with a much reduced binding constant, 103 M-1. CD studies showed [(en)Pt([special character]-dpzm)2Pt(en)]4+ was able to induce a DNA conformation change from B-type to what appeared to be a partial Z-type. Transcription assays showed that even though the metal complex does not bind DNA covalently, it is still able to inhibit DNA transcription at particular sites. The complexes di-Pt, tri-Pt, [{Pt(dien)}2[special character]-dpzm]4+ and trans-[Pt(NH3)2([special character]-dpzm)2]2+ were tested for anti-cancer activity in the L1210 murine leukaemia cell line, and gave values of 3.8, 2.5, [special character]200 and 64 [special character]M respectively. In the cisplatin resistant line (L1210/DDP), trans-[Pt(NH3)2([special character]-dpzm)2]2+ showed an increase in activity with a drop to 32 [special character]M, while both di-Pt and tri-Pt showed decreases in activity to values of 8.8 and 3.6 [special character]M. In the human ovarian carcinoma 2008 cell line and its cisplatin resistant derivative C13[special character]5, both complexes showed good activity with values of 2.5 and 20.9 [special character]M respectively, but again both showed decreases in activity in the resistant line with values of 17.8 and 37.7 [special character]M respectively. To help explain the difference between activity of these complexes and the complexes BBR3464 and BBR3005, cell uptake and DNA interstrand cross-linking experiments were performed. The cell uptake studies showed that both di-Pt and tri-Pt are taken up by cells at very high levels, when administered at 100 [special character]M, thus indicating that the difference is unlikely to be due to large differences in cell uptake. The DNA interstrand cross-linking studies showed both complexes readily form interstrand adducts (50% interstrand cross-linking at 12 nM and 22 nM respectively, c.f cisplatin 3 [special character]M). These results suggest that the rigid nature of the dpzm linker may be affecting the DNA adducts formed, with more interstrand links being formed than BBR3464. Possibly, it is this that causes the large differences in cytotoxicity. The DNA binding of di-Pt and tri-Pt was examined with the nucleosides adenosine and guanosine and the dinucleotide d(GpG). Both complexes bound at the N7 of guanosine, but 2-fold slower than cisplatin. In addition, di-Pt bound at the N7 and either the N1 or N3 of adenosine, 7-fold slower than guanosine. Di-Pt forms a large variety of cross-links between two d(GpG) molecules, however it could not be established whether the 1,2-intrastrand adduct could be formed. Di-Pt, however, forms a 1,2-GG interstrand adduct with the oligonucleotide d(ATGCAT)2 resulting in a conformation change away from B-type DNA. The sugar pucker of the G3 nucleoside changes from 2[special character]-endo towards 3[special character]-endo, and the position of the nucleotide relative to the sugar changes from anti to syn. The ability of multi-nuclear platinum complexes to form covalent adducts in the DNA minor groove remains unclear. It appears that di-Pt can form up to 33% minor groove adducts with the oligonucleotide d(AT)5, but when added to the oligonucleotide d(GCCAAATTTCCG)2 no definite minor groove adducts are seen and the major adduct appears to be a 1,2-interstrand cross-link between the two A6's or between the G1 and G11. Finally, a study of the encapsulation of platinum complexes within cucurbit[7]uril (Q7) as a means of reducing drug toxicity was made. For complex A and di-Pt, encapsulation of the linker ligand occurred. The effect of Q7 on the rate of hydrolysis of di-Pt was at least a 3-fold reduction as compared to free di-Pt with guanosine. Studies with [{Pt(dien)}2[special character]-dpzm]4+/Q7 and the oligonucleotide d(CGCGAATTCGCG)2 showed that the metal complex could dissociate from the Q7 and associate with the oligonucleotide, where an equilibrium is achieved with 15 % of the metal complex bound to the oligonucleotide and 75 % encapsulated in Q7. Tests in the L1210 and L1210/DDP cancer cell lines showed that di-Pt/Q7 has almost the same activity compared to free di-Pt.
APA, Harvard, Vancouver, ISO, and other styles
2

Bugarcic, Tijana. "Ruthenium arene anti-cancer complexes." Thesis, University of Edinburgh, 2008. http://hdl.handle.net/1842/13265.

Full text
Abstract:
This thesis is concerned with the synthesis and characterization of novel RuII arene anti-cancer complexes, containing different arenes and chelating ligands, especially arenes that can act as intercalators and chelating ligands that are redox-active. Synthesis and characterization of complexes of the type [(H6-arene)Ru(en)Cl]+, where the arene is ortho-, meta- or para-terphenyl (o-, m- or p-terp) are reported. [(H6-p-terp)Ru(en)Cl]+ has a similar potency to cisplatin and much higher activity against cancer cell lines than o- and m-terp analogues. The p-terp complex binds to DNA rapidly and quantitatively and the experimental data are consistent with combined intercalative and monofunctional (coordination) binding mode of [(H6-p-terp)Ru(en)Cl]+. The o- and m-terp analogues bind to DNA preferentially through coordination of ruthenium. The synthesis and characterization of RuII arene complexes containing 2,2’-bipyridine (bipy), 2,2’-bipyridine-3,3’-diol (bipy(OH)2) or deprotonated 2,2’-bipyridine-3,3’-diol (bipy(OH)O) as chelating ligands and different arenes are reported, including several x-ray crystal structures. In aqueous solution only the deprotonated (bipy(OH)O) form of the 2,2’-bipyridine-3,3’-diol is present in the complexes. Hydrolysis of these complexes in aqueous solution is relatively fast (37°C) and when the arene is biphenyl, initial aquation is followed by partial arene loss. Complexes with bipy(OH)O as chelating ligands, in general exhibit good cytotoxicity towards A2780 human ovarian cancer cells. Oxidation of the o-phenylenediamine (o-pda) chelating ligand in [(H6-arene)Ru(o-pda)Cl]+ to o-benzoquinonediimine (o-bqdi) leads to loss of cytotoxic activity. The x-ray crystal structures of [(H6-p-cym)Ru(o-pda)Cl][PF6] and [(H6-hmb)Ru(o-bqdi)Cl][PF6] are reported.
APA, Harvard, Vancouver, ISO, and other styles
3

Kuh, Hyo-Jeong. "Target site pharmacokinetics of anti-AIDS and anti-cancer agents /." The Ohio State University, 1997. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487943341527965.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lau, Kelvin Kar Wing. "Vascular targeting of anti-cancer therapy." Thesis, University of Oxford, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.311869.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cao, Siyu. "Designer bacteria as anti-cancer agents." Thesis, Griffith University, 2013. http://hdl.handle.net/10072/366498.

Full text
Abstract:
To date, cancer persists as one of the most devastating diseases worldwide. Problems such as inoperable primary tumours due to late stage diagnosis, presence of metastatic tumours, and tumour resistance to chemotherapy and radiotherapy have remarkably limited the therapeutic effects of existing treatments. To address these problems, cancer gene therapy has been under rapid development over the past two decades, which is specifically designed to deliver therapeutic genes to treat cancers using vector systems. However, the lack of an ideal vector has been a major drawback. Recent understanding of hypoxic and necrotic regions within solid malignancies and rapid development of recombinant DNA technology have reignited the idea of using anaerobic bacteria such as Clostridium as novel intra-tumoural delivery systems for anti-cancer therapeutics. These bacterial vectors have unique advantages over other delivery systems and are likely to become the vector of choice for cancer therapy in the near future. At present, Clostridium-mediated cancer therapy has shown some promising therapeutic efficacy against a number of solid malignancies, providing an opportunity for the development of novel anti-cancer gene therapies. In the last decade, targeted cancer therapy has witnessed its most impressive progress. Anti-cancer monoclonal antibodies (mAb) and recombinant immunotoxins against specific tumour cell surface antigens such as epidermal growth factor receptor (EGFR) have shown encouraging therapeutic efficacy against a large spectrum of cancers. However, difficulties such as insufficient intra-tumoural drug delivery have been preventing the therapy from reaching its full therapeutic potentials.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Medical Science
Griffith Health
Full Text
APA, Harvard, Vancouver, ISO, and other styles
6

Lyu, Jun Fang. "Discovery of cholesterol trafficking inhibitors as novel anti-angiogenic and anti-cancer agents." Thesis, University of Macau, 2018. http://umaclib3.umac.mo/record=b3953967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Deng, Zhao. "Anti-microbial and Anti-cancer activity of Traditional Chinese Medicine extracts." Thesis, Griffith University, 2020. http://hdl.handle.net/10072/401446.

Full text
Abstract:
Currently, the treatment of pathogenic microbial infections involves the use of a suitable antibiotic or combination of antibiotics. Unfortunately, the development of drug resistance in microbes is a serious problem. Hence it is necessary to find alternative treatments. Traditional Chinese medicines (TCMs) have been widely used since ancient times in China to treat the diseases caused by microbial infections. This suggests that the TCMs can potentially have anti-microbial activity against selected pathogenic microbes. This study firstly focused on the anti-microbial activity of 24 selected TCM extracts and demonstrated anti-microbial activities of several TCM extractss against three reference microbial strains (P. aeruginosa (Gram negative), S. aureus (Gram positive), and C. albicans (Fungus)). Two TCM extracts were shown to have inhibitory activity against P. aeruginosa, 14 TCM extracts were effective against S. aureus, and 3 TCM extracts were effective against the growth of C. albicans. In addition to the development of antibiotics, TCMs also has been used as additives in health products to overcome health problems caused by microbes and improve human body health. For example, body odour is caused by the overgrowth of C. jeikeium. Thus, the treatment of body odour can be achieved by inhibiting the growth of C. jeikeium. This study tested the anti-bacterial activity of 24 selected TCM extracts against C. jeikeium, 10 of which inhibited this bacteria’s growth. Those 10 TCM extracts can be potentially used as resources from which new deodorant ingredients could be developed. From preliminary data, three TCM extracts were selected for further investigation. Of those selected TCM extracts, TARAXACI HERBA (Pu Gong Ying, TH), which had efficacy against P. aeruginosa, was also tested for its ability to inhibit the growth of P. aeruginosa in shampoo. However, results showed that TARAXACI HERBA did not inhibit the growth of P. aeruginosa in the shampoo tested in this project. Cancer is a disease with severe adverse effects. Multiple myeloma (MM) is an incurable blood cancer that has concerned human society for a long time. Although recent chemotherapy advances have successfully improved the overall survival of MM patients, the development of drug resistance to current treatments makes it necessary to develop a new therapy. All three selected TCMs (COPTIDIS RHIZOMA (CR), TARAXACI HERBA (TH), and LONICERAE JAPONICAE FLOS (LJF)) have previously demonstrated anti-cancer or anti-tumour activity and another TCM, which was available in our lab (Xanthium), also has reported anti-cancer activity. Thus, four TCM extracts were tested for their ability to inhibit the proliferation of myeloma cells. Results showed that all four TCM extracts inhibited the cell proliferation of three different myeloma cell line including a bortezomib (BTZ) resistant RPMI cell line. However, only CR and TH have no toxicity to human fibroblast cells when they are killing cancer cells. A further study was conducted to determine whether the cell proliferation inhibition activity of the four TCM extracts is due to the ability to inhibit thioredoxin reductase (TrxR) activity. Although results indicate that all four TCM extracts can have significant effects on the reactive oxygen species (ROS) level in different myeloma cell lines, only treatment with LJF resulted in the inhibition of TrxR activity in myeloma cell lines. In conclusion, this project confirmed the anti-microbial activity of several TCM extracts among the original 24 selected TCMs. Interestingly, three of the TCM originally selected due to their anti-microbial activity are also able to inhibit cell proliferation of myeloma cells, including a BTZ resistant cell line. However, only one TCM extract (LJF) has the ability to inhibit TrxR activity in myeloma cells.
Thesis (Masters)
Master of Science (MSc)
School of Environment and Science
Science, Environment, Engineering and Technology
Full Text
APA, Harvard, Vancouver, ISO, and other styles
8

Qi, Ji. "Cane Toad Skin Extracts as Anti-Inflammatory and Anti-Cancer Agents." Thesis, Griffith University, 2016. http://hdl.handle.net/10072/365729.

Full text
Abstract:
The skin of the toads is known to be rich in bufadienolide compounds (a group of cardiac glycosides) that exhibit antitumor activity. For example, Huachansu (Cinobufacini), the aqueous extracts from the dried toad skin of Bufo bufo gargarizans Cantor or Bufo melanostictus Schneider, has been widely used in clinical therapy for various cancers in China. Clinical data have indicated that Cinobufacini may have significant anticancer activity with low toxicity and few side effects. Data to date suggest that treatment with Cinobufacini may also enhance the quality of life for patients with cancer. Huachansu contains several groups of compounds including peptides, bufadienolides/cardiac glycosides, cholesterols, indole alkaloids, bufogargarizanines, organic acid, and others. Bufadienolides, such as bufalin, cinobufagin, resibufogenin, and telocinobufagin, are responsible for the anti-cancer properties of Huachansu through disruption of the cell cycle and consequent inhibition of cell proliferation, induction of apoptosis, suppression of the NF-B pathway, immunomodulation and reversal of multi-drug resistance. The Australian cane toad (Bufo marinus) is also known as a source of bufadienolides, therefore is also considered as a new source of candidate lead compounds for drug development. Previous studies have shown that cane toad skin aqueous extracts (CTSAE) exhibited a stronger cardiac glycosides-like activity than the extracts of other organic solvents and have a suppression effect on Na+, K+‐ATPase in experimental models. However, no assay was performed to clarify the chemical constituents and pharmaceutical effects of CTSAE on cancer cells in previous studies.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Medical Science
Griffith Health
Full Text
APA, Harvard, Vancouver, ISO, and other styles
9

Wu, Na. "Identification of anti-resorptive and anti-cancer activities of epigenetic inhibitors." Thesis, University of Oxford, 2017. http://ora.ox.ac.uk/objects/uuid:9ae1e4e5-32b2-40e7-8249-5983d3e1bd6e.

Full text
Abstract:
Multiple myeloma is a plasma cell malignancy and develops in the bone marrow. The myeloma bone disease is present in the majority of the myeloma patients and is characterised by the excessive numbers and increased resorptive functions of osteoclasts. In order to identify novel targets controlling both osteoclastogenesis and myeloma cell growth, a library of epigenetic compounds was screened in an osteoclast differentiation assay and myeloma cell viability assay. Some compound classes, such as BET bromodomain inhibitors and HDAC inhibitors, showed inhibitory effects on both osteoclast differentiation and myeloma cell proliferation, suggesting that chromatin modifying reagents are possible therapeutic targets in multiple myeloma treatment. To rapidly screen for anti-osteoclast effects, an osteoclast RANKL gene card was successfully developed and applied to selected inhibitors in osteoclast assays. Moreover, the transcriptomic analysis was used to investigate the underlying mechanisms of selected epigenetic compounds in myeloma cells, and we found that cell cycle related pathways have been regulated by several inhibitors. Furthermore, an antibody panel for CyTOF (Mass cytometry) has been developed to characterise the bone marrow microenvironment of myeloma patients, and the CyTOF experiments demonstrated that GSK-J4 and rocilinostat activate the apoptosis marker caspase3 only in myeloma cells without affecting other cell populations. GSK-J4, an inhibitor for KDM5 and KDM6, was shown to upregulate the metallothioneins and induce the ATF4-mediated stress response in myeloma cells, whereas the KDM5B inhibitors causes cell cycle arrest rather than apoptosis.
APA, Harvard, Vancouver, ISO, and other styles
10

Trapika, I. Gusti Made Gde Surya Chandra. "Anti-Cancer Activity of Dendrobium chrysotoxum in human prostate cancer cells." Thesis, The University of Sydney, 2020. https://hdl.handle.net/2123/22501.

Full text
Abstract:
Dendrobium is one of the most valuable herbs in traditional Chinese medicine (TCM). It’s bibenzyl compounds demonstrate promising anti-cancer properties. Prostate cancer is the second most common cancer in men with estimated 1.1 million new cases and 0.8 million deaths per year in 2012. While Dendrobium’ anti-cancer activities has been explored in several cancer cell lines, the investigation of their bioactivity on prostate cancer is generally limited. Therefore, this thesis examines bioactivity and molecular mechanisms of selected Dendrobium species and their isolated chemical constituents in the three prostate cancer cell lines, LNCaP, an androgen dependent prostate cancer cell line, PC3 and DU-145, two non-dependent androgen cell lines. The study began with the screening of ten Dendrobium species commonly used in TCM practice, Dendrobium anosnum, D. aphyllum, D. devonianum, D. officinale, D. nobile, D. loddigesi, D. parisii, D. fimbriatum, D. aduncum, and D. chrysotoxum. Bioassay-guided fractionation techniques were applied to isolate and characterise the active compounds of the Dendrobium species that possess anti-cancer activity against the three prostate cancer cells. The crude extract of all ten Dendrobium species showed promising inhibitory effects on the three selected prostate cancer cell lines at a concentration of 20µg/mL. D. chrysotoxum exhibited the strongest anti-cancer activity which was then subjected to further investigation. Isolation, purification and elucidation procedures revealed that erianin is the predominant bibenzyl compound in D. chrysotoxum and is responsible for its anti-cancer activity. Our initial findings confirmed that erianin, is highly abundant in D. chrysotoxum, whereas other studies showed it is present in a much lower amounts in other Dendrobium species. Dendrobium species vary widely in their chemical constituents, and several factors including geographic, climatic and season of harvesting influence their quantity and quality. Hence, the almost exclusive presence of erianin in D. chrysotoxum could be applied for standardization and quality control of the anti-cancer properties of this Dendrobium species. Erianin exhibited anti-cancer activity in prostate cancer cells with an IC50 value below 50nM signifying its potency as a promising anti-cancer agent. At 24 hours of treatment, the IC50 of erianin for LNCaP cells is about twice the IC50 of PC3, while at a longer treatment times, the IC50 values of the two prostate cancer cells lines were similar, of 32.96nM for LNCaP and 36.06nM for PC3, at 72 hours of treatment. While erianin exhibits strong inhibition of cancer cell viability, erianin has no effect on the migration of either LNCaP and PC3 cells. The anti-cancer mechanism of erianin was further explored on LNCaP and PC3 cells representing the two different types in androgen dependence of prostate cancer. Erianin showed a different anti-cancer mechanism of action between the two prostate cancer cell lines. In androgen sensitive LNCaP, erianin induced apoptosis and autophagy. However, in androgen insensitive PC3 cells it induced autophagy and G2/M phase arrest. This thesis then compares erianin’s anti-cancer mechanism in prostate cancer cells with the mechanisms that have been identified in other previously studied cancer cell lines and discusses the underlying mechanism of erianin anticancer bioactivity. The anti-cancer activity of erianin on prostate cancer cell lines through induced apoptosis, autophagy and cell cycle arrest aligns with its bioactivity in other cell lines. Our study lays the essential findings of the potency of erianin against both androgen dependent and androgen independent prostate cancer cells, further elucidation of the mechanism and validation with in vivo experiments are required.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Anti-cancer"

1

Louise, Rivard. 200 recettes anti-cancer. Montréal: Modus vivendi, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gregory, Christopher D., ed. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-39406-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hortobagyi, Gabriel N., and David Khayat, eds. Progress in Anti-Cancer Chemotherapy. Paris: Springer Paris, 1999. http://dx.doi.org/10.1007/978-2-8178-0918-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Khayat, David, and Gabriel N. Hortobagyi, eds. Progress in Anti-Cancer Chemotherapy. Paris: Springer Paris, 2000. http://dx.doi.org/10.1007/978-2-8178-0920-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

David, Khayat, and Hortobagyi Gabriel N, eds. Progress in anti-cancer chemotherapy. Malden, Mass., USA: Blackwell Science, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Eastwood, P. R. Synthesis of new purine anti-viral and anti-cancer agents. Manchester: UMIST, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Malik, Sonia, ed. Biotechnology and Production of Anti-Cancer Compounds. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-53880-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Atta-ur-Rahman and Khurshid Zaman, eds. Topics in Anti-Cancer Research Volume 6. UAE: Bentham Science Publishers Ltd., 2017. http://dx.doi.org/10.2174/97816810845581170601.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Garth, Powis, and Prough Russell A, eds. Metabolism and action of anti-cancer drugs. London: Taylor & Francis, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Yost, Debora. The anti-cancer food and supplement guide. New York: St. Martin's Paperbacks, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Anti-cancer"

1

Sarafraz-Yazdi, Ehsan, and Josef Michl. "Anti-Cancer Peptides." In Encyclopedia of Cancer, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_7132-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mudaliar, Priyanka, Apoorva Jagannath Nalawade, Priyamvada Arte, Akanksha Dhuliya, Deepak Iyer, Kanchanlata Tungare, Mustansir Bhori, and Jyotirmoi Aich. "Anti-Cancer Phytopharmaceuticals." In Phytopharmaceuticals and Biotechnology of Herbal Plants, 239–54. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/b22917-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sarafraz-Yazdi, Ehsan, and Josef Michl. "Anti-Cancer Peptides." In Encyclopedia of Cancer, 270–73. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-46875-3_7132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chen, Xin, Tao Liu, Pingyun Yuan, Xiaowei Chang, Qiqi Yin, Wenyun Mu, and Zhenzhen Peng. "Anti-cancer Nanotechnology." In Nanomedicine, 1–50. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-13-9374-7_11-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kuswantoro, Farid, and Stephen P. Teo. "Anti-Cancer Plants." In Medicinal Plants of Borneo, 33–39. 1st edition. | Boca Raton : CRC Press, 2021. | Series: Natural products chemistry of global plants: CRC Press, 2021. http://dx.doi.org/10.1201/9780429470332-5-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dunlap, Norma, and Donna M. Huryn. "Anti-cancer drugs." In Medicinal Chemistry, 287–318. New York, NY : Garland Science, Taylor & Francis Group, LLC, [2018]: Garland Science, 2018. http://dx.doi.org/10.1201/9781315100470-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Magalhães, Flávia F., João C. F. Nunes, Marília T. Araújo, Ana M. Ferreira, Mafalda R. Almeida, Mara G. Freire, and Ana P. M. Tavares. "Anti-Cancer Biosurfactants." In Environmental and Microbial Biotechnology, 159–96. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-6607-3_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Xin, Tao Liu, Pingyun Yuan, Xiaowei Chang, Qiqi Yin, Wenyun Mu, and Zhenzhen Peng. "Anti-cancer Nanotechnology." In Nanomedicine, 389–438. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-16-8984-0_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bumbăcilă, Bogdan, Corina Duda-Seiman, Daniel Duda-Seiman, and Mihai V. Putz. "Cancer/Anti-Cancer Chemotherapy: Pharmacological Management." In New Frontiers in Nanochemistry, 57–84. Includes bibliographical references and indexes. | Contents: Volume 1. Structural nanochemistry – Volume 2. Topological nanochemistry – Volume 3. Sustainable nanochemistry.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429022951-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Szabados, Bernadett, and Thomas Powles. "Urological Anti-cancer Agents." In Basic Urological Sciences, 289–301. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9780429285813-33.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anti-cancer"

1

Li, Jiachen. "Recent Advancements of Anti-cancer Nanomedicine in Breast Cancer." In The International Conference on Biomedical Engineering and Bioinformatics. SCITEPRESS - Science and Technology Publications, 2022. http://dx.doi.org/10.5220/0011192400003443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, Jeong-Won. "Anti-cancer effect of penfluridol in epithelial ovarian cancer." In KSGO 2023. Korea: Korean Society of Gynecologic Oncology, 2023. http://dx.doi.org/10.3802/jgo.2023.34.s1.o02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kwon, Byoung S., Hanna Lee, Jin Sung Park, SeungHee Han, Sungmin Park, Sun Woo x Im, HyunTae Son, and Joseph H. Jeong. "1063 Anti-4–1BB x PD-1, a bispecific anti-cancer therapeutics." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.1063.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tran, Phong, and Thomas J. Webster. "Novel anti-cancer orthopedic materials: Nanostructured selenium." In 2007 IEEE 33rd Annual Northeast Bioengineering Conference. IEEE, 2007. http://dx.doi.org/10.1109/nebc.2007.4413367.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lally, Beth, Robert Gettens, and Shabnam Sani. "Delivery of Anti-Cancer Drugs Using Nanocarriers." In 2013 39th Annual Northeast Bioengineering Conference (NEBEC). IEEE, 2013. http://dx.doi.org/10.1109/nebec.2013.74.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

He, Yuwei, Chang Liu, and Linkun Zhang. "Artemisinin Derivatives: Anti-cancer Effects and Mechanisms." In The International Conference on Biomedical Engineering and Bioinformatics. SCITEPRESS - Science and Technology Publications, 2022. http://dx.doi.org/10.5220/0011211500003443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wagner, Gerhard, Evangelos Papadopoulos, Tingfang Yi, Melissa Leger-Abraham, and Naotaka Sekiyama. "Abstract IA23: eIF4E as anti-cancer target." In Abstracts: AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; October 27-30, 2016; San Francisco, CA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.transcontrol16-ia23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Isaeva, O. G., and V. A. Osipov. "Photodynamic therapy influence on anti-cancer immunity." In Saratov Fall Meeting 2009, edited by Valery V. Tuchin and Elina A. Genina. SPIE, 2009. http://dx.doi.org/10.1117/12.853588.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jeong, Yoo Kyung, Go Eun Heo, Keun Young Kang, Dong Sup Yoon, and Min Song. "Analyzing the Landscape of Anti-Cancer Drug Research in Pancreatic Cancer." In CIKM'15: 24th ACM International Conference on Information and Knowledge Management. New York, NY, USA: ACM, 2015. http://dx.doi.org/10.1145/2811163.2811177.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Berzofsky, Jay, William Becker, and Purevdorj Olkhanud. "813 Cancer vaccine triple synergistic combination immunotherapy enhances anti-cancer efficacy." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0813.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Anti-cancer"

1

Tung, Ching-Hsuan. Protease Mediated Anti-Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, August 2006. http://dx.doi.org/10.21236/ada458446.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ruoslahti, Erkki I. New Anti-Metastatic and Anti-Angiogenic Compound for Ovarian Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2001. http://dx.doi.org/10.21236/ada406191.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rouslahti, Erkki I. New Anti-Metastatic and Anti-Angiogenic Compound for Ovarian Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2003. http://dx.doi.org/10.21236/ada420794.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sokoloff, Mitchel H. Neoadjuvant Anti-Angiogenesis Therapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2004. http://dx.doi.org/10.21236/ada437213.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ponnazhagan, Selvarangan. Anti-Angiogenic Gene Therapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, April 2005. http://dx.doi.org/10.21236/ada443094.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Su, Min-Ying L. Anti-Angiogenesis Therapeutic Indicators in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2004. http://dx.doi.org/10.21236/ada429932.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ponnazhagan, Selvarangan. Anti-Angiogenic Gene Therapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2006. http://dx.doi.org/10.21236/ada460463.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Weinberg, Andrew D. Enhancing Anti-Prostate Cancer Immunity through OX40 Engagement. Fort Belvoir, VA: Defense Technical Information Center, February 2005. http://dx.doi.org/10.21236/ada437192.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vieweg, Johannes. Enhancement of Anti-Telomerase Immunity Against Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, November 2007. http://dx.doi.org/10.21236/ada485726.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Weiner, Louis M. Targeting Breast Cancer With Anti-HER2/neu Diabodies. Fort Belvoir, VA: Defense Technical Information Center, July 2002. http://dx.doi.org/10.21236/ada407429.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anti-cancer' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography